Standout Papers

Tezacaftor–Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis 2017 2026 2020 2023 353
  1. Tezacaftor–Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis (2017)
    Steven M. Rowe, Cori Daines et al. New England Journal of Medicine

Immediate Impact

2 by Nobel laureates 4 from Science/Nature 50 standout
Sub-graph 1 of 22

Citing Papers

Artificial intelligence-guided design of lipid nanoparticles for pulmonary gene therapy
2024 Standout
Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders
2024 Standout
2 intermediate papers

Works of Nitin Nair being referenced

Tezacaftor–Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis
2017 Standout
Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfa
2013

Author Peers

Author Last Decade Papers Cites
Nitin Nair 34 123 264 358 164 34 918
Prashilla Soma 16 181 267 278 115 33 800
George Grimes 22 173 313 142 117 35 1.0k
Kaoru Hamada 43 205 309 312 93 36 934
John H. Grindlay 18 81 94 274 137 56 1.0k
D. J. Deller 4 100 194 98 110 49 1.1k
Rafael L. Perez 52 174 176 437 207 37 1.1k
Kazutaka Nishimura 26 188 84 373 156 45 809
Mingyo Kim 23 324 81 130 128 31 846
Viviènne Verweij 25 295 198 87 71 34 940
Yung-Yang Liu 7 321 151 361 73 42 977

All Works

Loading papers...

Rankless by CCL
2026